Cortex (Cor) [formerly CORX] Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cortex (Cor) [formerly CORX]

COR 329.85

-8.8%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: kenhott	6/18/2008 3:04:33 PM
	Read Replies (1) of 1255

<reply> DSMB, the key words are safety and data. Efficacy comes into play for the DSMB when it touches on to safety, at the two extremes. "No chance" and the trial is stopped to prevent patients from dealing with a drug with no obvious chance for benefit. "Outstanding" and the trial is stopped so people can get off placebo and to allow the drug to progress to the next step. Data integrity is the other piece. In this situation, I am guessing it is data related. When the DSMB went to look, they found reasons in the quality of the data to want more patients. As usual, a simplified view and just an opinion.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next